CVS Health Corporation announced its financial results for the second quarter of 2025, reporting a total revenue increase to $98.9 billion, an 8.4% rise compared to the prior year. The company's GAAP diluted earnings per share $(EPS)$ decreased to $0.80 from $1.41 in the previous year, influenced by two litigation charges related to past business practices. The adjusted EPS remained steady at $1.81 compared to the prior year. The company also updated its full-year 2025 guidance, adjusting the GAAP diluted EPS range to $3.84 to $3.94, down from the previous range of $4.23 to $4.43. However, the adjusted EPS guidance range was raised to $6.30 to $6.40 from $6.00 to $6.20. Furthermore, CVS Health increased its cash flow from operations guidance to at least $7.5 billion, up from approximately $7.0 billion. Key operational developments included Aetna's advancements in care navigation, CVS Pharmacy's agreement to acquire certain prescription files and store locations from Rite Aid, and CVS Caremark's market-leading innovations during a strong renewal and sales season.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.